Skip to main content

Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients

Abstract

Background

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is hallmarked by a significant reduction in natural killer (NK) cell cytotoxicity, a mechanism tightly regulated by calcium (Ca2+). Interestingly, interleukin-2 (IL-2) increases NK cell cytotoxicity. Transient receptor potential melastatin 2 (TRPM2) ion channels are fundamental for Ca2+ signalling in NK cells. This pilot investigation aimed to characterise TRPM2 and CD38 surface expression in vitro on NK cells in ME/CFS patients. This investigation furthermore examined the pharmaceutical effect of 8-bromoadenosine phosphoribose (8-Br-ADPR) and N6-Benzoyladenosine-3′,5′-cyclic monophosphate (N6-Bnz-cAMP) on TRPM2 and CD38 surface expression and NK cell cytotoxicity between ME/CFS and healthy control (HC) participants.

Methods

Ten ME/CFS patients (43.45 ± 12.36) and 10 HCs (43 ± 12.27) were age and sex-matched. Isolated NK cells were labelled with fluorescent antibodies to determine baseline and drug-treated TRPM2 and CD38 surface expression on NK cell subsets. Following IL-2 stimulation, NK cell cytotoxicity was measured following 8-Br-ADPR and N6-Bnz-cAMP drug treatments by flow cytometry.

Results

Baseline TRPM2 and CD38 surface expression was significantly higher on NK cell subsets in ME/CFS patients compared with HCs. Post IL-2 stimulation, TRPM2 and CD38 surface expression solely decreased on the CD56DimCD16+ subset. 8-Br-ADPR treatment significantly reduced TRPM2 surface expression on the CD56BrightCD16Dim/− subset within the ME/CFS group. Baseline cell cytotoxicity was significantly reduced in ME/CFS patients, however no changes were observed post drug treatment in either group.

Conclusion

Overexpression of TRPM2 on NK cells may function as a compensatory mechanism to alert a dysregulation in Ca2+ homeostasis to enhance NK cell function in ME/CFS, such as NK cell cytotoxicity. As no improvement in NK cell cytotoxicity was observed within the ME/CFS group, an impairment in the TRPM2 ion channel may be present in ME/CFS patients, resulting in alterations in [Ca2+]i mobilisation and influx, which is fundamental in driving NK cell cytotoxicity. Differential expression of TRPM2 between NK cell subtypes may provide evidence for their role in the pathomechanism involving NK cell cytotoxicity activity in ME/CFS.

Background

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disabling condition characterized by unexplained chronic fatigue that is associated with immune, neurological (including autonomic), musculoskeletal, cardiovascular and gastrointestinal symptoms [1, 2]. Currently, accurate diagnosis remains challenging in the absence of a clinical or laboratory test. Although the aetiology of ME/CFS remains undefined, immunological dysfunction has been consistently implicated in this condition. Notably, a significant reduction in natural killer (NK) cell cytotoxicity is a consistent feature in ME/CFS patients compared with healthy control (HC) participants [3,4,5,6].

NK cells are granular lymphocytes of the innate immune system, principally responsible for recognising and responding to pathogen invasion [7]. NK cells are also essential to combat viral and microbial infection, as well as tumour development [7]. NK cells are located in peripheral blood, spleen, bone marrow and lymph nodes, and stem from the CD34 hematopoietic progenitor cell lineage [7]. At least five NK populations have been classified, however the two predominant human subsets include CD56DimCD16+ and CD56BrightCD16dim/− populations. Approximately 90% of peripheral NK cells are CD56DimCD16+ which are highly cytotoxic and kill infected, tumour or ‘missing self’ cells [8]. Comparatively, the CD56BrightCD16Dim/− subset are primarily involved in immunosurveillance and cytokine production [9]. Interestingly, IL-2-activated NK cells are more lytic to target cells than resting NK cells [10,11,12].

The IL-2 receptor (IL-2R) is a heterotrimeric protein expressed on a number of immune cells that binds and responds to IL-2 [13, 14]. The IL-2R comprises three forms: α (alpha) (also called IL-2Rα, CD25), β (beta) (also called IL-2Rβ or CD122) and γ (gamma) (also called IL-2Rγ or CD132). Binding of IL-2 promotes Janus tyrosine Kinase (JAK) 1 and JAK 3 enzyme activation, in turn initiating the Mitogen-Activated Protein Kinase (MAPK), phosphoinositide 3-kinase (PI3K), and the Signal Transducer and Activator of Transcription (STAT) pathways [15]. Activation of these pathways enhances NK cell cytotoxic function, known as lymphokine-activated killing (LAK). NK cells are the predominant effector cells within LAKs, which are mechanistically equivalent to peripheral blood NK cells [16], but possess enhanced cytotoxic potential against an extensive spectrum of cell targets [17]. IL-2 has been postulated to be possibly involved in the de novo expression of proteins that act between CD38 and the lytic machinery in NK cells [10].

Calcium (Ca2+) plays a fundamental role in various cellular mechanisms such as intracellular signalling pathways, cell differentiation, cell division, apoptosis and transcriptional events. Notably, intracellular Ca2+ is crucial for target cell adhesion, immune synapse formation, granule polarization and degranulation, all of which are essential for NK cells to mediate their natural cytotoxicity [8, 18]. One fundamental signalling pathway involved in intracellular Ca2+ is the store-operated calcium entry (SOCE) mechanism [19]. Recently, the transient receptor potential channel (TRP) family has emerged as a potential SOCE candidate [19, 20].

TRP channels are a unique group of ion channels that function as polymodal cell sensors due to their extensive sensitivity to physical and chemical stimuli. TRP channel activation follows deviations in the cellular environment, including pathogens, temperature, pressure, chemicals, oxidation and reduction, toxins, osmolarity and pH [21, 22]. Transient receptor potential melastatin 2 (TRPM2) is a homo-tetrameric nonselective cation permeable channel localised in the plasma membrane and lysosomal compartments [23]. The protein is highly expressed in the brain, immune system, endocrine cells, and endothelia [24]. TRPM2 uniquely possesses dual ion channel functionality and enzymatic ADP-ribose (ADPR) hydrolase activity [21].

TRPM2 is primarily activated in a synergistic fashion by low micromolar levels of cytosolic ADPR and Ca2+ [23]. At a cellular level, ADPR is predominantly produced by the hydrolysis of NAD+ and/or cADPR by glycohydrolases, including the ectoenzyme, CD38 [23]. CD38 uses NAD+ to generate various Ca2+ mobilizing secondary messengers, such as ADPR, cADPR and NAADP [23, 24]. Direct binding to the enzymatic NUDT9-H domain activates and opens the channel, subsequently facilitating the permeation of sodium (Na2+), potassium (K+) and Ca2+ into the cell and hydrolysis of ADPR to ribose 5-phosphate and adenosine monophosphate (AMP) [25]. Importantly, TRPM2 activation increases intracellular free calcium concentration ([Ca2+]i) [26, 27], which can mediate signalling roles in inflammatory and secretory by releasing vesicular mediators (i.e. cytokines, neurotransmitters), as well as apoptosis and necrotic cell death under oxidative stress [23].

A recent in vivo mouse investigation discovered a novel anti-tumour mechanism in NK cells via a ADPR-CD38 synergy with TRPM2 [28]. This investigation highlighted three fundamental steps of this synergistic pathway: (1) activation of intracellular CD38 by protein kinase A following NK cell recognition of a tumour cell results in ADPR production; (2) ADPR targets TRPM2 channels on cytolytic granules, and (3) TRPM2-mediated Ca2+ signalling causes cytolytic granule polarisation and degranulation, resulting in anti-tumour activity [28]. These results suggest that CD38, ADPR and TRPM2 are key components in mediating Ca2+-induced anti-tumour activity in NK cells [28].

Pharmacologically, TRPM2 currents can be inhibited by altering the production of TRPM2 secondary messengers [24]. Pharmacological antagonists reviewed in the literature include: 8-Br-cADPR (cADPR antagonist) [29], 8-Br-ADPR (ADPR antagonist) [30], nifedipine, econazole [31] flufenamic acid [31], imidazole antifungal agents [31], anthranilic acid, N-(p-amycinnamoyl) [32] and 2-APB [32]. However, majority of these molecules are insufficiently potent and do not exhibit high TRPM2 specificity [24].

To date, no potent pharmacological TRPM2 agonists have been reported, however N6-Benzoyladenosine-3′,5′-cyclic monophosphate (N6-Bnz-cAMP) has been identified as a weak TRPM2 agonist through indirect stimulation via protein kinase A (PKA) production, most likely through phosphorylation [33].

Characterisation of TRPM2 has predominantly been studied with in vivo models, primarily by genetic knockdown [28, 33,34,35,36,37,38,39,40]. Although in vitro investigations of TRPM2 have also been examined in T cells, macrophages, SCC9 cells, and HEK293 cells [36, 39, 41, 42] there have been no in vitro TRPM2 models studied on human NK cells. Given TRPM2 is critical for Ca2+ homeostasis and NK cell cytotoxicity, this is the first in vitro investigation to examine NK cell cytotoxicity following TRPM2 modulation with N6-Bnz-cAMP and 8-Br-ADPR in ME/CFS patients. Secondly, this study aims to characterise TRPM2 surface expression on NK cell subsets to determine whether differential expression of TRPM2 plays a role in ME/CFS patients compared with HC.

Methods

Study participants

A total of 11 ME/CFS and 11 HC participants were selected for this pilot investigation. Two participants were excluded due to outlier values. Participants were sourced from the National Centre of Neuroimmunology and Emerging Diseases (NCNED) database for ME/CFS between January and April 2019. Participants were excluded if they were pregnant or breastfeeding, or reported a previous history of smoking, alcohol abuse or chronic illness (for example, autoimmune diseases, cardiac diseases and primary psychological disorders). Participants donated 85 ml of whole blood in ethylenediaminetetraacetic acid (EDTA) tubes between 8:30 am and 10:00 am on the Gold Coast, Queensland, Australia. Full blood count was performed within 4 h (hr) of blood collection for each participant. All participants provided written consent and the study was approved by the Griffith University Human Research Ethics Committee (HREC/15/QGC/63).

Peripheral blood mononuclear cell isolation and natural killer cell isolation

Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by centrifugation over a density gradient medium (Ficoll-Paque Premium; GE Healthcare, Uppsala, Sweden) to separate granulocytes as previously described [3, 43]. PBMCs were stained with trypan blue stain (Invitrogen Life Technologies, Carlsbad, CA, USA) to determine total cell count and cell viability and adjusted to a final concentration of 5 × 107 cells/ml. NK cells were isolated from PBMCs using an EasySep Negative Human NK Cell Isolation Kit (Stemcell Technologies, Vancouver, BC, Canada). NK cell purity was measured following staining with CD56-Pe-Cy7 (0.25 µg/5 µl) and CD3-APC-H7 (0.5 µg/5 µl) antibodies (Beckon Dickinson [BD] Bioscience, Miami, FL, USA) for 20 min (min) at room temperature in the dark and analysed using a LSR-Fortessa X20 flow cytometer (BD Biosciences, Miami, FL, USA). NK cell purity was 92.46 ± 2.375 for HCs and 93.58 ± 0.9282 for ME/CFS, respectively (Additional file 1).

Interleukin-2 stimulation

NK cells were stimulated with 20 IU/ml of recombinant human IL-2 (specific activity 5 × 106 IU/mg) per test (Miltenyi Biotech, BG, Germany) and incubated for 24 h at 37 °C with 5% CO2 in Roswell Park Memorial Institute medium (RPMI)-1640 (Invitrogen Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen Life Technologies, Carlsbad, CA, USA).

Drug treatment

IL-2 stimulated NK cells were treated with the following drugs at a final concentration of 100 μM N6-Bnz-cAMP, and 100 μM 8-Br-ADPR for 30 min at 37 °C with 5% CO2 in RPMI-1640 (Invitrogen Life Technologies, Carlsbad, CA, USA) supplemented with 10% FBS (Invitrogen Life Technologies, Carlsbad, CA, USA)). All drugs were purchased from Bio-Techne (Tocris Bioscience, Sussex, UK). Labelled cells were washed with 2 ml of RPMI-1640 supplemented with 10% FBS and centrifuged at 250 g for 5 min. Supernatant was removed prior to NK lysis and TRPM2 immunophenotyping.

TRPM2 immunophenotyping assay

Following magnetic NK cell isolation, baseline TRPM2 and CD38 surface expression was measured as previously described [44] NK cells were stained with trypan blue stain (Invitrogen Life Technologies, Carlsbad, CA) to determine live cell count and cell viability and adjusted to a final concentration of 1.1 × 106 cells/ml. NK cells were incubated with an Fc receptor Blocking reagent (Miltenyi Biotech, Bergisch Gladbach. Germany) for 10 min at 4 °C prior to antibody staining. NK cells were incubated with primary fluorochrome labelled antibodies [CD3-APCH7 (0.5 µg/5 µl), CD56-PeCy7 (0.25 µg/5 µl), CD16-BV650 (0.25 µg/5 µl), and CD38-BV480 (1 µg/5 µl)] purchased from BD Biosciences), in addition to an unconjugated rabbit IgG polyclonal extracellular TRPM2 antibody (1:50) (OST00112W) (Thermo Fisher Scientific, Waltham, MA, USA) for 2 h at 4 °C in the dark.

Labelled cells were washed with stain buffer (BD Biosciences, Miami, FL, USA) and centrifuged at 350g for 5 min. Supernatant was removed and cells were incubated with a secondary Goat F(ab) Anti-Rabbit IgG H&L Fluorescein isothiocyanate (FITC) (1:500) (ab7050) (Abcam, UK) in 200 μl for 1 h at 4 °C in the dark. Cells were washed and stained with 5 µl of 7-AAD (BD Bioscience, New Jersey, USA) to measure cell viability. Cells were resuspended in 200 µl of stain buffer (BD Bioscience, Miami, FL, USA) and acquired at 10,000 events using the LSRFortessa X-20. Furthermore, TRPM2 and CD38 surface expression was measured following drug treatment.

Normal rabbit serum (1:50) (01-6101) (Thermo Fisher Scientific, Waltham, MA, USA) was used as a negative control to determine an individualised positive TRPM2 gate for each participant (Additional file 2). Additionally, an unstained tube (unlabelled NK cells); a secondary tube (secondary antibody only); and a Fluorescence Minus One (FMO) (CD56, CD3, CD16 and CD38) control were performed for each participant. Normalised TRPM2 and CD38 surface expression was calculated by compensating the percentage of fluorescence spill over into the B525/50 (TRPM2) and V525/50 (CD38) as outlined below for TRPM2:

$$TRPM2\,Surface\,Expression\, = \,TRPM2\,Stained\,tube\,\left( {parent \, \% } \right)\, - \,Normal\,Rabbit\,Serum\,\left( {parent \, \% } \right)$$

Natural killer cell cytotoxicity assay

NK cytotoxic activity was conducted as previously described [43, 45, 46]. NK cells were labelled with Paul Karl Horan (PKH-26) (3.5 µl/test) Sigma-Aldrich, St. Louis. MO, USA) for 5 min (and incubated with K562 cells for 4 h at 37 °C with 5% CO2 in RPMI-1640 supplemented with 10% FBS. The concentration of NK cells and K562 cells was adjusted to 5 × 105 cells/ml and 1 × 106 cells/ml, respectively. During incubation, cells were combined at effector target (E:T) ratios of 25:1, 12.5:1 and 6.25:1 in addition to control samples (only 25:1 NK lysis ratio shown). Control and IL-2 treated cells were stained using Annexin V (2.5 µl/test) (BD Bioscience, Miami, FL, USA) and 7-AAD (2.5 µl/test) (BD Bioscience, Miami, FL, USA) to determine apoptosis using flow cytometry analysis recording 10,000 events. E:T ratio of 25:1, 12.5:1, 6.25:1 (only 25:1 NK lysis ratio shown) and control were used to assess cytotoxic activity. NK cytotoxic activity was calculated as percent specific death of the K562 cells for the three E:T ratios as previously described [43, 45, 46] and outlined below:

$$Cytotoxicity\,\left( \% \right) = \frac{{\left( {early\;stage\;apoptosis\; + \;late\;stage\;apoptosis\; + \;dead\;K562\;cells} \right)}}{All\;K562\;Cells}\; \times \;100$$

LSR Fortessa X-20 flow cytometry analysis

Lymphocyte populations were identified using forward and side scatter dot plots. Exclusions were CD3+ cells and only CD3 lymphocytes were further used to characterise NK cell subset populations using CD56 and CD16. NK cell subsets were characterised using the surface expression of CD56BrightCD16Dim/−NK cells and CD56DimCD16Bright/+ NK cells. TRPM2 and CD38 surface expression was measured as percentage of parent cells (%) and NK cytotoxicity was measured as percentage of K562 cell death (%).

Statistical analysis

Pilot data from this investigation were analysed using SPSS version 24 (IBM Corp, Version 24, Armonk, NY, USA) and GraphPad Prism, version 7 (GraphPad Software Inc., Version 7, La Jolla, CA, USA). Shapiro–Wilk normality tests were conducted to determine the distribution of data, in addition to skewness and kurtosis tests to determine data normality. The independent Mann–Whitney U test was performed to determine the statistical significance between and within groups in TRPM2 parameters on NK cells. Significance was set at p < 0.05 and the data are presented as mean ± standard error of the mean unless otherwise stated.

Results

Participant demographics

A total of 20 participants (10 HC and 10 ME/CFS patients) were included for this present study and no significant differences in age and gender were reported between groups (Table 1). Additionally, ME/CFS patients reported greater impairment compared with HCs in all Short-Form Health Survey (SF-36) subscales (lower score indicate greater impairment; p < 0.001), with the exception of emotional wellbeing. Full blood count parameters were measured for each participant. All participant results were within the specified reference ranges for each parameter and there were no significant differences between groups for these reporting parameters (Table 1).

Table 1 Participants’ demographic and serology results

Discussion

We have previously determined an optimal in vitro methodology to phenotype TRPM2 and CD38 surface expression on human NK cell subsets from HC participants using flow cytometry [44]. This current investigation is the first in vitro study to characterise TRPM2 and CD38 surface expression on peripheral NK cell subsets from ME/CFS patients. This is also the first study to examine the pharmacological effect of 8-Br-ADPR and N6-Bnz-cAMP drug treatments on TRPM2 and CD38 surface expression, as well as NK cell cytotoxicity in ME/CFS patients.

At baseline, TRPM2 surface expression was significantly higher in ME/CFS patients compared with HCs on CD56BrightCD16Dim/− and (Fig. 1a) and CD56DimCD16+ NK cells (Fig. 1b). These findings were also found at dual expression with CD38 on both NK cell subsets (Fig. 1c, d). CD38 surface expression alone was reportedly higher in ME/CFS and HC participants (99%) on both NK cell subsets (Fig. 2a, b). However, when compared with dual expression with TRPM2, CD38 surface expression decreased to 22% (ME/CFS) and 6% (HC) on both subsets (Fig. 1c, d). This difference with co-expression is reflective of CD38’s additional functions, independent of TRPM2, such as cell adhesion, signal transduction and Ca2+ signalling. However, as CD38 surface expression did not differ between groups, our results highlight an overexpression of the TRPM2 ion channel within the ME/CFS group. In comparison to the reductions in TRPM3 surface expression reported in our previous findings [45, 47], we postulate that this overexpression in TRPM2 may function as a compensatory mechanism to alert a dysregulation in Ca2+ homeostasis within the NK cell.

Fig. 1
figure1

TRPM2 and CD38 surface expression on CD56BrightCD16Dim/− and CD56DimCD16+ NK cell subsets between groups post IL-2 stimulation. At baseline, TRPM2 surface expression was significantly higher in the ME/CFS group compared to HCs on CD56BrightCD16Dim/− (a) and CD56DimCD16+ NK cells (b). A consistent finding was found at dual expression with CD38 on both NK cell subsets (c, d). Post IL-2 stimulation, TRPM2 with and without CD38 significantly decreased on the CD56DimCD16+ subset within the ME/CFS group (b, d). No significant differences in TRPM2 and CD38 surface expression were found within the HC group pre and post IL-2 stimulation in either NK cell subset

Fig. 2
figure2

CD38 surface expression on CD56BrightCD16Dim/− and CD56DimCD16+ NK cell subsets between groups post IL-2 stimulation. No significant difference in CD38 surface expression was found between groups or within either NK cell subset pre and post IL-2 stimulation (a, b). No significant changes in CD38 surface expression was observed post drug treatment between or within groups on either NK cell subset (c, d)

Ca2+ plays a fundamental role in intracellular signalling pathways, cell differentiation and cell division, apoptosis and transcriptional events [22,23,24]. Upon stimulation, Ca2+ permeable TRP channels, such as TRPM2, generate changes in [Ca2+]i, by acting as Ca2+ gatekeepers via the plasma membrane. Notably, [Ca2+]i is important to sensitise TRPM2 for activation by ADPR resulting in a positive feedback loop and Ca2+ entry [48, 49]. Changes in channel stoichiometry and assembly can induce significant dysregulations in Ca2+ mobilization [50, 51]. Thus, Ca2+ homeostasis requires a tight and meticulous regulation for efficient receptor functionality. An important Ca2+-dependent mechanism regulated by TRPM2 in NK cells is cytotoxic function.

Although the underlying aetiology of ME/CFS remains unknown; a significant reduction in NK cell cytotoxicity is a consistent laboratory finding in ME/CFS patients compared with HCs [3,4,5,6], which was confirmed in this present study (Fig. 3). In the ME/CFS group, an improvement in NK cell function was expected in correlation to the overexpression of TRPM2 as a compensatory mechanism (Fig. 1). However, as baseline NKcell cytotoxicity was significantly reduced in ME/CFS patients compared with HCs, these results may suggest an impaired and/or faulty TRPM2 ion channel within the ME/CFS group. An impairment in the TRPM2 ion channel function may prevent the permeabilization and influx of Ca2+ within the NK cell; resulting in a subsequent reduction in Ca2+ modulation and [Ca2+]i, thus leading to impaired Ca2+-dependent mechanisms, including NK cell cytotoxicity.

Fig. 3
figure3

Natural killer cell cytotoxicity after treatment with 8-Br-ADPR and N6-Bnz-cAMP between groups. At baseline, a significant increase in NK cell cytotoxicity was observed in HC participants compared with ME/CFS patients. Within the HC group, NK cell lysis decreased post IL-2 stimulation. This observation was not found within the ME/CFS group. No significant difference in NK cell cytotoxicity was observed between groups after drug treatments

Following IL-2 stimulation, NK cell cytotoxicity significantly decreased within the HC group (Fig. 3). This was an unexpected outcome as previous investigations have reported enhancements in NK cell cytotoxicity following IL-2 stimulation [10,11,12]. However, an in vivo mouse study discovered that IL-2 rapidly lowers the activation threshold of NK cells to adhere and engage with their targets [12]. Moreover, NK cell responses did not augment post IL-2 in the presence of inhibitory receptor signalling, suggesting potential interactions of the IL-2R with integrin or activating-receptor signalling pathways [12]. An additional rationale could reflect the limited culture time period (24 h), as most NK cell cultures range between 1 and 2 weeks [52,53,54,55,56]. However, as fresh human peripheral NK cells were used, a longer culture time period was not preferential as NK cell purity significantly decreases to 40–50% [57]. Conversely, no change in NK cell cytotoxicity was observed post IL-2 stimulation within the ME/CFS group (Fig. 3), which reinforces a significant impairment in the TRPM2 ion channel.

Interestingly, TRPM2 and CD38 surface expression significantly decreased after IL-2 stimulation in ME/CFS patients (Fig. 1). However, this finding was only observed on the CD56DimCD16+ NK cell subset within the ME/CFS group (Fig. 1a, c). A possible rationale may involve downregulation the IL-2Rα on the CD56DimCD16+ subset, which has been suggested to reduce the ability for efficient CD56DimCD16+ NK cell activation and restoration of proliferative capability in response to IL-2 [10].

Thus, a negative feedback mechanism, involving Ca2+, may be present between the IL-2Rα and TRPM2 and CD38 on CD56DimCD16+ NK cells in response to IL-2 as it has been proposed that IL-2 may induce the de novo expression of proteins that act between CD38 and the lytic machinery in NK cells [10]. The MAPK signalling pathway may be a potential candidate, as this pathway is activated by both IL-2 and major histocompatibility complex-1 receptor [16, 58], and may mimic mediation of the Ca2+-dependent steps of NK cytotoxicity. Importantly, we have previously shown a significant change in the MAPK Ca2+ dependent pathways for NK lysis in ME/CFS patients [45, 46].

Pharmacologically, TRPM2 currents can be inhibited by altering the production of TRPM2 secondary messengers, such as ADPR [24]. A former in vivo investigation evidenced 8-Br-ADPR as the sole secondary messenger to antagonise TRPM2 by blocking sustained tumour-induced Ca2+ signals and degranulation by western blot and confocal microscopy [28].

Within our ME/CFS group, TRPM2 surface expression significantly decreased following 8-Br-ADPR treatment (ADPR antagonist) on CD56BrightCD16Dim/− NK cells (Fig. 4a). Therefore, TRPM2 surface expression can be antagonised, but not effectively stimulated following agonists, such as N6-Bnz-cAMP (Fig. 4). Interestingly, this result differed with our previous TRPM3 surface expression findings following drug treatment from ME/CFS patients [45, 47]. Following 2‐aminoethoxydiphenyl borate treatment (non-selective TRPM inhibitor), TRPM3 surface expression remained unchanged on both NK cell subsets. Conversely, pregnenolone sulfate (TRPM3 agonist) treatment significantly increased TRPM3 surface expression on both NK cell subsets. Together, these findings reinforce the importance of Ca2+ for efficient TRP channel activity and highlight a consistent Ca2+ signalling dysregulation caused by impairments in TRPM ion channel expression and activity in ME/CFS patients. Moreover, as 8-Br-ADPR was administrated with IL-2, the selective diminishment of the TRPM2 ion channel may be due to the upregulation of the IL-2Rα on the CD56BrightCD16Dim/− subset.

Fig. 4
figure4

Pharmacological effect of 8-Br-ADPR and N6-Bnz-cAMP drug treatment on TRPM2 and CD38 surface expression on NK cell subsets. On CD56BrightCD15Dim/− NK cells (a), TRPM2 surface expression significantly decreased following treatment with 8-Br-ADPR within the ME/CFS group. No significant difference was observed on the CD56DimCD16+ NK cell subset for TRPM2 surface expression between and within groups (b). Moreover, no significant differences between or within groups were found on theCD56BrightCD15Dim/− (c) and CD56DimCD16+ (d) NK cell subsets for dual expression with TRPM2

Comparatively, no changes in NK cell cytotoxicity were observed in either group following 8-Br-ADPR and N6-Bnz-cAMP treatment (Fig. 3). These results may reflect the limited availability of specific pharmacological drugs to modulate TRPM2 ion channels. An extensive list of pharmacological agents have been reviewed in the literature including: 8-Br-cADPR (cADPR antagonist) [29], 8-Br-ADPR (ADPR antagonist) [30], N6-Bnz-cAMP (indirect CD38 agonist), nifedipine, econazole [31], flufenamic acid [31], imidazole antifungal agents [31], anthranilic acid, N-(p-amycinnamoyl) [32] and 2-APB [32]. Unfortunately, majority of these molecules are insufficiently potent and do not exhibit high TRPM2 specificity [24], which may explain the absent changes in NK cell cytotoxicity following drug treatment in both groups (Fig. 2).

An alternative rationale may involve different TRPM2 splice variants in ME/CFS patients. Within the literature, three primary TRPM2 isoforms have been established: SSF-TRPM2, TRPM2-ΔC and TRPM2-ΔN [41, 59]. Although the full-length TRPM2 can be activated by ADPR, NAD+ and H2O2, TRPM2 spliced isoforms cannot be significantly stimulated by these same activators [60,61,62]. Interestingly, Du et al. established that 10 µM [Ca2+]i can activate TRPM2-N, TRPM2-C, and TRPM2-N/C spliced isoforms in a concentration-dependent manner. These results suggest that [Ca2+]i may serve as an alternative in vivo activator of both full and spliced isoforms of TRPM2, thus conferring their physiological functions [63]. Whether spliced isoforms can form functional channels remains to be determined [60,61,62].

Our results are considered preliminary due to our small sample size. Resultantly, our significant findings warrant further investigation with a larger cohort as a key future direction. Importantly, a significant limitation within ME/CFS research is the absence of an in vivo model and/or cell line to represent this multifactorial disorder. Consequently, current in vitro methodologies are restricted to studying isolated cells from criteria-based ME/CFS patients. One method to target specific immunological pathways from patient cells is through pharmacological modulation. However, if the mechanism of action of these drugs is unknown or non-specific, severe limitations arise in the ability to analyse accurate and reliable data. Therefore, a vital future direction is the development of pharmacotherapeutic drugs with high efficacy and specificity to TRPM2. Access to these agents will enable the use of more sophisticated applications such as whole cell electrophysiology using patch clamp techniques. Genetic methodologies are an additional future direction to understand the role of TRPM2 in Ca2+ signalling and NK cell function.

Conclusion

This pilot study is the first to identify and characterise TRPM2 and CD38 surface expression on human NK cell subsets in vitro from ME/CFS patients. This investigation is also the first to examine the effects of IL-2, 8-Br-ADPR and N6-Bnz-cAMP drug treatment on TRPM2 and CD38 surface expression, as well as NK cell cytotoxicity. These new findings revealed a significant overexpression of TRPM2 on NK cells in ME/CFS patients. An overexpression in TRPM2 may function as a compensatory mechanism to alert a dysregulation in Ca2+ homeostasis and improve NK cell function. However, as baseline NK cell cytotoxicity was significantly reduced in ME/CFS patients compared with HCs, an impairment in the TRPM2 ion channel may result in alterations in [Ca2+]i, which is fundamental in driving NK cell cytotoxicity.

Differential expression of TRPM2 between NK cell subtypes may provide evidence for their role in the pathomechanism involving NK cell cytotoxicity activity in ME/CFS. The clinical potential of these results to develop a biological marker and drug interventions is yet to be determined.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due to confidentiality agreements but are available from the corresponding author on reasonable request.

Abbreviations

7-AAD:

7-amino-actinomycin

8-Br-ADPR:

8-bromoadenosine phosphoribose

ADPR:

adenosine diphosphoribose

BMI:

body mass index

BSA:

bovine serum albumin

BD:

becton dickinson

Ca2+ :

calcium

[Ca2+]i :

intracellular calcium

cADPR:

cyclic adenosine diphosphate ribose

cAMP:

cyclic adenosine monophosphate

EDTA:

ethylendiaminetetraacetic acid

FBS:

fetal bovine serum

FITC:

fluorescein isothiocyanate

H2O2 :

hydrogen peroxide

hr:

hour

IL-2:

interleukin-2

IL-2R:

interleukin-2 receptor

JAK:

janus tyrosine kinase

K+ :

potassium

LAK:

lymphokine-activated killing

min:

minute

N 6-Bnz-cAMP:

N6-benzoyladenosine-3′,5′-cyclic monophosphate

Na2+ :

sodium

NAADP:

nicotinic acid adenine dinucleotide phosphate

NAD+ :

nicotinamide adenine dinucleotide

NCNED:

national centre of neuroimmunology and emerging diseases

NK:

natural killer

MAPK:

mitogen-activated protein kinase

ME/CFS:

myalgic encephalomyelitis

PBMCs:

peripheral blood mononuclear cells

PI3K:

phosphoinositide 3-kinase

PKA:

protein kinase A

PKH-26:

paul karl horan-26

RBC:

red blood cell

RPMI:

roswell park memorial institute medium

SF-36:

short-form health survey

SOCE:

store operated calcium entry

STAT:

signal transducer and activator of transcription

TG:

thapsigargin

TRPM2:

transient receptor potential melastatin 2

WBC:

white blood cell

References

  1. 1.

    Fukuda K, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121(12):953–9.

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Carruthers BM, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270(4):327–38.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Brenu EW, et al. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2011;9(1):81.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Klimas NG, et al. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol. 1990;28(6):1403–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Brenu EW, et al. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2012;10(1):88.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Huth T, et al. Pilot study of natural killer cells in chronic fatigue syndrome/myalgic encephalomyelitis and multiple sclerosis. Scand J Immunol. 2016;83(1):44–51.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Mandal A, Viswanathan C. Natural killer cells: in health and disease. Hematol Oncol Stem Cell Ther. 2015;8(2):47–55.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Vivier E, et al. Functions of natural killer cells. Nat Immunol. 2008;9(5):503.

    CAS  Article  Google Scholar 

  9. 9.

    Draghi M, et al. Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I. Blood. 2005;105(5):2028–35.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Bryceson YT, et al. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107(1):159–66.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Lehmann C, Zeis M, Uharek L. Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells. Br J Haematol. 2001;114(3):660–5.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Gasteiger G, et al. IL-2–dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J Exp Med. 2013;210(6):1167–78.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Re GG, et al. Interleukin 2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res. 1996;56(11):2590–5.

    CAS  PubMed  Google Scholar 

  14. 14.

    Minami Y, et al. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol. 1993;11(1):245–68.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;33(2):153–65.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. 16.

    Grimm EA, et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155(6):1823–41.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Frederick M, et al. Cytokine-induced cytotoxic function expressed by lymphocytes of the innate immune system: distinguishing characteristics of NK and LAK based on functional and molecular markers. J Interferon Cytokine Res. 1997;17(8):435–47.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Schwarz EC, Qu B, Hoth M. Calcium, cancer and killing: the role of calcium in killing cancer cells by cytotoxic T lymphocytes and natural killer cells. BBA Mol Cell Res. 2013;1833(7):1603–11.

    CAS  Google Scholar 

  19. 19.

    Groschner K, Graier WF, Romanin C. Store-operated Ca2+ entry (SOCE) pathways. Emerg Signal concept Hum physiol. 2012;1993:3–13.

    Google Scholar 

  20. 20.

    Majewski L, Kuznicki J. SOCE in neurons: signaling or just refilling? BBA Mol Cell Res. 2015;1853(9):1940–52.

    CAS  Google Scholar 

  21. 21.

    Nieto-Posadas A, Jara-Oseguera A, Rosenbaum T. TRP channel gating physiology. Curr Top Med Chem. 2011;11(17):2131–50.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Moran MM, et al. Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov. 2011;10(8):601.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Nilius B, et al. Transient receptor potential cation channels in disease. Physiol Rev. 2007;87(1):165–217.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Sumoza-Toledo A, Penner R. TRPM2: a multifunctional ion channel for calcium signalling. J Physiol. 2011;589(7):1515–25.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Venkatachalam K, Montell C. TRP channels. Annu Rev Biochem. 2007;76:387–417.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Howard M, et al. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science. 1993;1993:1056–9.

    Article  Google Scholar 

  27. 27.

    Burnay MM, et al. Role of the capacitative calcium influx in the activation of steroidogenesis by angiotensin-II in adrenal glomerulosa cells. Endocrinology. 1994;135(2):751–8.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Rah S-Y, et al. ADP-ribose/TRPM2-mediated Ca2+ signaling is essential for cytolytic degranulation and antitumor activity of natural killer cells. Sci Rep. 2015;5:9482.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  29. 29.

    Kolisek M, et al. Cyclic ADP-ribose and hydrogen peroxide synergize with ADP-ribose in the activation of TRPM2 channels. Mol Cell. 2005;18(1):61–9.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Partida-Sanchez S, et al. Chemotaxis of mouse bone marrow neutrophils and dendritic cells is controlled by adp-ribose, the major product generated by the CD38 enzyme reaction. J Immunol. 2007;179(11):7827–39.

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Hill K, et al. Flufenamic acid is a pH-dependent antagonist of TRPM2 channels. Neuropharmacology. 2004;47(3):450–60.

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Kraft R, et al. Inhibition of TRPM2 cation channels by N-(p-amylcinnamoyl) anthranilic acid. Br J Pharmacol. 2006;148(3):264–73.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Uchida K, Tominaga M. The role of TRPM2 in pancreatic β-cells and the development of diabetes. Cell Calcium. 2014;56(5):332–9.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Rah S-Y, et al. Generation of cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate by CD38 for Ca2+ signaling in interleukin-8-treated lymphokine-activated killer cells. J Biol Chem. 2010;285(28):21877–87.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  35. 35.

    Rah S-Y, et al. Activation of CD38 by interleukin-8 signaling regulates intracellular Ca2+ level and motility of lymphokine-activated killer cells. J Biol Chem. 2005;280(4):2888–95.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Hill K, et al. Characterisation of recombinant rat TRPM2 and a TRPM2-like conductance in cultured rat striatal neurones. Neuropharmacology. 2006;50(1):89–97.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Oda S, et al. TRPM2 contributes to antigen-stimulated Ca2 + influx in mucosal mast cells. Pflügers Archiv Eur J Physiol. 2013;465(7):1023–30.

    CAS  Article  Google Scholar 

  38. 38.

    Haraguchi K, et al. TRPM2 contributes to inflammatory and neuropathic pain through the aggravation of pronociceptive inflammatory responses in mice. J Neurosci. 2012;32(11):3931–41.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Yamamoto S, et al. TRPM2-mediated Ca2+ influx induces chemokine production in monocytes that aggravates inflammatory neutrophil infiltration. Nat Med. 2008;14(7):738.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Hardaker L, et al. The ion channel transient receptor potential melastatin-2 does not play a role in inflammatory mouse models of chronic obstructive pulmonary diseases. Respir Res. 2012;13(1):30.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Uemura T, et al. Characterization of human and mouse TRPM2 genes: identification of a novel N-terminal truncated protein specifically expressed in human striatum. Biochem Biophys Res Commun. 2005;328(4):1232–43.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Melzer N, et al. TRPM2 cation channels modulate T cell effector functions and contribute to autoimmune CNS inflammation. PLoS ONE. 2012;7(10):e47617.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  43. 43.

    Hardcastle SL, et al. Characterisation of cell functions and receptors in chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). BMC Immunol. 2015;16(1):35.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  44. 44.

    Balinas C, Cabanas H, Staines D, Marshall-Gradisnik S. Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry. BMC Immunol. 2019;20:14.

    PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Nguyen T, et al. Novel identification and characterisation of transient receptor potential melastatin 3 ion channels on natural killer cells and B lymphocytes: effects on cell signalling in chronic fatigue syndrome/myalgic encephalomyelitis patients. Biol Res. 2016;49(1):27.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Huth TK, Staines D, Marshall-Gradisnik S. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/− natural killer cells in chronic fatigue syndrome/myalgic encephalomyelitis patients. J Transl Med. 2016;14(1):97.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  47. 47.

    Nguyen T, et al. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels. Clin Exp Immunol. 2017;187(2):284–93.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Starkus J, et al. Regulation of TRPM2 by extra-and intracellular calcium. J General Physiol. 2007;130(4):427–40.

    CAS  Article  Google Scholar 

  49. 49.

    Csanády L, Törőcsik B. Four Ca2+ ions activate TRPM2 channels by binding in deep crevices near the pore but intracellularly of the gate. J General Physiol. 2009;133(2):189–203.

    Article  CAS  Google Scholar 

  50. 50.

    Ji W, et al. Functional stoichiometry of the unitary calcium-release-activated calcium channel. Proc Natl Acad Sci. 2008;105(36):13668–73.

    CAS  PubMed  Article  Google Scholar 

  51. 51.

    Ji W, et al. Functional stoichiometry of the unitary calcium-release-activated calcium channel revealed by single-molecule imaging. Biophys J. 2009;96(3):560a.

    Article  Google Scholar 

  52. 52.

    Handa K, et al. Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production. J Immunol. 1983;130(2):988–92.

    CAS  PubMed  Google Scholar 

  53. 53.

    Wagner J, et al. A two-phase expansion protocol combining interleukin (il)-15 and il-21 improves natural Killer cell Proliferation and cytotoxicity against rhabdomyosarcoma. Front Immunol. 2017;8:676.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  54. 54.

    Imamura M, et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood. 2014;124(7):1081–8.

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Becker PS, et al. Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol Immunother. 2016;65(4):477–84.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  56. 56.

    Cho D, Campana D. Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med. 2009;29(2):89–96.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Selvan SR, Dowling JP. “Adherent” versus other isolation strategies for expanding purified, potent, and activated human NK cells for cancer immunotherapy. Biomed Res Int. 2015;2015:869547.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  58. 58.

    Yu T-K, et al. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J Immunol. 2000;164(12):6244–51.

    CAS  PubMed  Article  Google Scholar 

  59. 59.

    Wehage E, et al. Activation of the cation channel long transient receptor potential channel 2 (LTRPC2) by hydrogen peroxide A splice variant reveals a mode of activation independent of ADP-ribose. J Biol Chem. 2002;277(26):23150–6.

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Kühn FJ, Lückhoff A. Sites of the NUDT9-H domain critical for ADP-ribose activation of the cation channel TRPM2. J Biol Chem. 2004;279(45):46431–7.

    PubMed  Article  CAS  Google Scholar 

  61. 61.

    Perraud A-L, Schmitz C, Scharenberg AM. TRPM2 Ca2+ permeable cation channels: from gene to biological function. Cell Calcium. 2003;33(5–6):519–31.

    CAS  PubMed  Article  Google Scholar 

  62. 62.

    Kühn FJ, Heiner I, Lückhoff A. TRPM2: a calcium influx pathway regulated by oxidative stress and the novel second messenger ADP-ribose. Pflügers Archiv. 2005;451(1):212–9.

    PubMed  Article  CAS  Google Scholar 

  63. 63.

    Du J, Xie J, Yue L. Intracellular calcium activates TRPM2 and its alternative spliced isoforms. Proc Natl Acad Sci. 2009;106(17):7239–44.

    CAS  PubMed  Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

All the authors undertook the study design and collection, analysis, interpretation of data and in writing the manuscript. Funding bodies only provided financial support towards this study. Funding bodies included: the Stafford Fox Medical Research Foundation (489798), McCusker Charitable Foundation (49979), Buxton Foundation (4676), Henty Community (4879), Henty Lions Club (4880), Mason Foundation (47107), Mr Douglas Stutt, Blake Beckett Trust Foundation (4579), Alison Hunter Memorial Foundation (4570) and the Change for ME Charity (4575). Funding bodies

Author information

Affiliations

Authors

Contributions

CB performed the experiment. HC, DS and SMG participated in study coordination and contributed substantially reviewing the draft manuscript. CB performed the data analysis. CB interpreted the data analysis and drafted the manuscript. CB and SMG designed the study. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Cassandra Balinas.

Ethics declarations

Ethics approval and consent to participate

All participants provided written consent and the study was approved by the Griffith University Human Research Ethics Committee (HREC/15/QGC/63).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Balinas, C., Cabanas, H., Staines, D. et al. Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients. J Transl Med 17, 401 (2019). https://doi.org/10.1186/s12967-019-02155-4

Download citation

Keywords

  • Adenosine diphosphate ribose
  • Calcium
  • Myalgic encephalomyelitis/chronic fatigue syndrome
  • Interleukin-2
  • Natural killer cells
  • Transient receptor potential melastatin 2